Latest news
RAPP: RAP-219 shows robust efficacy in drug-resistant epilepsy, advancing to Phase 3 with strong financial backing - TradingViewTradingView · Wed, 05 Aug 2026 13:38:22 GMTQTTB: Bempikibart shows strong efficacy and safety in severe alopecia areata, supporting Phase 3 advancement - TradingViewTradingView · Wed, 05 Aug 2026 11:39:41 GMTMRK: Long-acting oral HIV regimens show strong efficacy and market potential, targeting $5B+ by mid-2030s - TradingViewTradingView · Mon, 03 Aug 2026 14:08:31 GMTMPLT: Phase 2 ZEPHYR met its primary endpoint, showing robust efficacy and cognitive benefit in schizophrenia - TradingViewTradingView · Mon, 27 Jul 2026 07:00:00 GMT